Shots:

• The study will evaluate BBP-398 in combination with Lumakras including a dose-escalation period which will be followed by dose expansion and optimization. BridgeBio will be sponsoring the study and Amgen will provide a global supply of Lumakras
• BridgeBio is advancing its P-I clinical trial of BBP-398 in patients with solid tumors with the KRAS G12C mutation. This program is a part of company’s precision oncology pipeline and one of the 14 programs being advanced in the clinic or commercial setting
• BBP-398 is a small-molecular inhibitor of SHP2 which is a protein-tyrosine phosphatase that links growth factor, cytokine, and integrin signaling with the downstream RAS/ERK MAPK pathway for regulating cellular proliferation and survival

Ref: Bridgebio | Image: PR Newswire